Teva’s Therapy for Chorea in Huntington’s Disease, SD-809, Shows Effect in 12-Week Clinical Trial
Results from a Phase 3 clinical trial found that deutetrabenazine (SD-809), an investigational drug developed by Teva Pharmaceutical Industries, improved chorea among Huntington’s disease patients. But the researchers caution that more studies are needed to ascertain the treatment’s long-term effectiveness and safety. Data from the trial showing that the drug improved swallowing…